Laboratory Tests for Liver Function and Clinical Uses of ELF, NAG, and GGT
Standard Liver Function Tests
The commonly ordered "liver function tests" are actually markers of hepatocellular damage rather than true liver function, and include AST, ALT, GGT, alkaline phosphatase (ALP), and bilirubin 1. True liver function tests measure synthetic capacity (albumin, clotting factors) or metabolic capacity, but these are ordered less frequently in routine practice 1.
The standard panel for initial liver assessment includes:
- AST (aspartate aminotransferase) and ALT (alanine aminotransferase) - markers of hepatocellular injury
- GGT (gamma-glutamyl transferase) - marker of biliary disease and alcohol use
- ALP (alkaline phosphatase) - marker of cholestasis
- Bilirubin - marker of hepatic excretory function
- Platelet count - decreases with advanced fibrosis/cirrhosis
For risk stratification in patients with suspected chronic liver disease, guidelines recommend checking AST, ALT, GGT, ALP, and platelet count as the initial screening panel 2.
Enhanced Liver Fibrosis (ELF) Test
The ELF test is a proprietary blood test that measures three molecules involved in liver matrix turnover to assess the severity of liver fibrosis non-invasively, serving as an alternative to liver biopsy 3, 4.
Clinical Uses of ELF:
For NAFLD/MASLD:
- ELF ≥9.8 is the recommended cut-off to rule-in advanced fibrosis in alcohol-related liver disease (ALD) and NAFLD when transient elastography is unavailable 2
- ELF <7.7 has sensitivity >0.90 for excluding fibrosis, making it excellent for rule-out in low-prevalence settings 4
- For balanced diagnostic accuracy in MASLD: ELF ≥9.80 identifies advanced fibrosis (≥F3) with 70% sensitivity and 79% specificity 5
- ELF ≥11.30 identifies cirrhosis (F4) with high specificity (96%) but lower sensitivity (21%) 5
- ELF ≥10.50 represents a practical upper threshold for therapeutic decision-making regarding anti-fibrotic therapy 5
Key Performance Characteristics:
The ELF test excels at ruling out advanced fibrosis in low-prevalence populations (such as primary care), where its negative predictive value is highest 4, 6. However, in low-prevalence settings, positive predictive value is limited, requiring additional testing strategies for confirmation 4.
In a study of 128 patients with 6% prevalence of advanced fibrosis, ELF (cut-off 10.5) demonstrated good specificity for excluding advanced fibrosis 2. The test is useful across primary, secondary, and tertiary care settings for early recognition, accurate prognosis, and treatment monitoring 6.
N-acetyl-β-D-glucosaminidase (NAG)
Urinary NAG (u-NAG) is primarily a renal tubular damage biomarker used to detect early diabetic kidney disease, but emerging evidence suggests it may also reflect hepatic fibrosis severity in type 2 diabetes 7.
Clinical Uses of NAG:
- Primary use: Early marker of renal tubular damage in diabetic kidney disease
- Emerging use: Higher urinary NAG-to-creatinine ratios independently predict more advanced hepatic fibrosis in patients with type 2 diabetes (β=1.58, P<0.01) 7
- Patients with elevated u-NAG show nearly 2-fold increased odds of higher hepatic fibrosis stage (F2: OR 1.99,95% CI 1.04-3.82) 7
This association likely reflects the common metabolic pathways linking renal and hepatic fibrosis in diabetes, though validation studies are needed before routine clinical application for liver assessment 7.
Gamma-Glutamyl Transferase (GGT)
GGT is a widely used marker of liver dysfunction, alcohol intake, and biliary disease, but also serves as an independent predictor of metabolic disease and cardiovascular risk 8.
Clinical Uses of GGT:
For liver disease assessment:
- Marker of cholestasis and biliary obstruction
- Sensitive indicator of alcohol consumption - conditions increasing GGT (obstructive liver disease, alcohol, enzyme-inducing drugs) lead to increased oxidative stress 8
- In alcohol-related liver disease, GGT >2× upper limit of normal indicates hepatic inflammation requiring repeat liver stiffness measurement after ≥1 week of alcohol abstinence 2
For metabolic disease monitoring:
- After weight loss in MASLD, GGT decreases by approximately 38% at 12 months, correlating with reduction in liver fat (r=0.38, p=0.013) 9
- If baseline GGT is >40 IU/L, a decrease has 87.5% positive predictive value for reduction in liver fat content 9
- GGT is an independent predictor of type 2 diabetes risk, metabolic syndrome, coronary heart disease, and stroke 8, 10
- Higher GGT levels associate with increased all-cause mortality 8
Physiological Context:
GGT breaks down extracellular glutathione, making amino acids available for intracellular antioxidant defense 8. However, the products of this reaction can paradoxically increase free radical production, particularly in the presence of iron 8. This dual role explains both its protective function and its association with oxidative stress-related diseases.
Practical Algorithm for Liver Assessment
Based on EASL 2021 guidelines 2:
- Screen patients at risk (metabolic syndrome, alcohol use, viral hepatitis, family history)
- Check initial panel: AST, ALT, GGT, ALP, platelet count
- Calculate FIB-4 score (uses age, AST, ALT, platelets)
- FIB-4 <1.3: Rules out advanced fibrosis
- FIB-4 >2.67: Suggests advanced fibrosis
- If FIB-4 indeterminate or elevated:
- Use ELF test (cut-off 9.8 for NAFLD/ALD) if available
- Or proceed to transient elastography
- Monitor GGT response to interventions (weight loss, alcohol cessation) as a practical marker of liver fat reduction
Important Caveats:
- ALT and GGT changes reliably reflect liver fat changes only when baseline values are elevated (>40 IU/L) 9
- In patients with elevated liver stiffness and AST or GGT >2×ULN, repeat testing after alcohol abstinence is mandatory to avoid false positives 2
- ELF test performance depends heavily on disease prevalence in your practice setting - adjust interpretation accordingly 4